Back

LncRNA-mediated organization of oncogenic chromatin state is a targetable vulnerability in leukemia

Vu, L. P.; Jin, Z.; Ma, B.; Chan, K.; Lin, D.; Ghosh, D.; Louwagie, A.; Saville, L.; Chandra, J. L.; Liu, Y.; Liu, Z.; Escano, L.; Miko, S. S.; Cheng, S. W. G.; Stricker, P.; Edin, G.; Wong, F.; Dong, K.; Hoang, Q. A.; Bui, Q. T. T.; Schurer, A.; Do, K.; Chou, T.; Oakes, C.; Basha, G.; Sauvageau, M.; Hussein, S. M. I.; Morin, G.; Perna, F.; Kuchenbauer, F.; Kharas, K. G.; Karsan, A.; Cullis, P. R.

2026-08-11 cancer biology
10.64898/2026.08.10.744058 bioRxiv
Show abstract

Long non-coding RNAs (lncRNAs) are increasingly recognized as critical regulators of gene expression underlying various cellular functions, however, the functional and mechanistic contributions of most lncRNAs to tumorigenesis remain poorly defined, and targeting of lncRNAs is challenging with conventional therapeutic approaches. Here, we uncover human PAN3-AS1 and its murine ortholog Lnc35682, previously uncharacterized lncRNAs embedded within a conserved syntenic genomic locus, as highly expressed in acute myeloid leukemia (AML). Using genetic mouse models, human cell lines and primary patient samples, we show that PAN3-AS1 is essential for leukemia maintenance but dispensable for normal hematopoiesis. Mechanistically, we find that elevated PAN3-AS1 influences chromatin accessibility, thus promoting leukemia gene expression programs. This is mediated, at least in part, by PAN3-AS1s association with the nuclear lamina through a defined functional region that is required for its leukemogenic function. We further characterize a feed-forward regulatory circuit between PAN3-AS1 and its neighboring gene FLT3 that directly links the aberrant lncRNA functions to the FLT3-mutant AML subtype. To therapeutically exploit the regulatory node, we engineer a myeloid leukemia-preferentially targeted lipid nanoparticle (LNP) formulation and demonstrate effective delivery of siRNAs against endogenous targets into leukemia cells in experimental animals. LNP-siPAN3-AS1 alone or in combination with a clinically used FLT3 inhibitor, Gilteritinib, reduces leukemia burden and significantly delay leukemogenesis in vivo. Overall, our study uncovers a therapeutic vulnerable lncRNA-centric circuitry and provides compelling preclinical evidence for the development and application of a novel RNA targeting-LNP based therapy for treatment of myeloid leukemia. Graphical abstract O_FIG O_LINKSMALLFIG WIDTH=200 HEIGHT=200 SRC="FIGDIR/small/744058v1_ufig1.gif" ALT="Figure 1"> View larger version (52K): org.highwire.dtl.DTLVardef@b1d833org.highwire.dtl.DTLVardef@1e8fda6org.highwire.dtl.DTLVardef@164d39corg.highwire.dtl.DTLVardef@80c747_HPS_FORMAT_FIGEXP M_FIG C_FIG

Matching journals

The top 6 journals account for 50% of the predicted probability mass.

50% of probability mass above

"Similar papers" are the closest papers from that journal in the model's embedding space. They show what the match is built on, but the ranking comes mostly from a classifier over the whole training set, not from these examples alone.